Caris Life Sciences, Inc.
CAI
$27.24
$1.134.33%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | |||
|---|---|---|---|---|---|
| Revenue | 113.38% | 81.31% | 49.88% | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | 113.38% | 81.31% | 49.88% | ||
| Cost of Revenue | 21.18% | 8.35% | 17.02% | ||
| Gross Profit | 232.13% | 202.72% | 118.51% | ||
| SG&A Expenses | 20.14% | 33.65% | 9.51% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 13.37% | 19.35% | 3.45% | ||
| Operating Income | 153.65% | 73.16% | 37.16% | ||
| Income Before Tax | 135.92% | -8.47% | 7.61% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | 135.92% | -8.47% | 7.61% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | 135.92% | -8.47% | 7.61% | ||
| EBIT | 153.65% | 73.16% | 37.16% | ||
| EBITDA | 174.56% | 79.10% | 31.69% | ||
| EPS Basic | 103.33% | -213.88% | 6.12% | ||
| Normalized Basic EPS | 104.54% | 55.66% | 8.41% | ||
| EPS Diluted | 103.09% | -213.88% | 6.12% | ||
| Normalized Diluted EPS | 104.31% | 55.66% | 8.41% | ||
| Average Basic Shares Outstanding | 691.44% | 83.54% | 0.88% | ||
| Average Diluted Shares Outstanding | 733.84% | 83.54% | 0.88% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||